Quantum Genesis AI Corp. (OTC: QGAI) issued a statement on May 19, 2026, to clarify the nature of its research activities and intellectual property rights. The company distinguished itself from Quantumzyme LLP, a separate entity based in Bengaluru, India, which was referenced in prior press releases dated November 5, 2025 and February 12, 2026. Quantumzyme LLP is not a subsidiary or affiliate of Quantum Genesis AI.
The clarification stems from earlier disclosures that cited scientific publications related to enzyme engineering and biocatalysis. Those publications listed Quantumzyme LLP and reflected the affiliations of researchers at the time the work was conducted. Quantum Genesis AI now explicitly states that Quantumzyme LLP is a distinct entity, and the company is providing additional context regarding intellectual property (IP) rights previously transferred under an Asset Purchase Agreement dated February 21, 2023, and a subsequent confirmatory assignment filed on April 29, 2026.
According to the statement, scientific publications arising from research by Chief Executive Officer Naveen Kulkarni appropriately reflect his affiliations at the time of submission. However, the company believes that the Asset Purchase Agreement transferred underlying technology, methodologies, computational approaches, know-how, and related IP associated with its core enzyme engineering and biocatalysis business. To the extent that research by Mr. Kulkarni—whether directly or through Quantumzyme LLP—relates to these transferred assets, the company asserts that such IP falls within the scope of rights transferred to Quantum Genesis AI.
The company’s prior disclosures referencing scientific publications were made based on its ownership of relevant IP and technology. This clarification aims to provide transparency and avoid confusion about the relationship between the entities.
Quantum Genesis AI Corp. is a biotechnology company focused on enzyme engineering, molecular modeling, and biocatalysis. It leverages advanced data-driven tools for research and technology development. The company’s stock trades on the OTC Markets under the ticker QGAI. For more information, visit qgaicorp.com and the company’s profile on OTC Markets.
This press release contains forward-looking statements subject to risks and uncertainties. The company undertakes no obligation to update these statements. Readers should conduct their own due diligence and consult professional advisors before making investment decisions.
